MedTrace Logo

Study to Investigate the Interaction Between FG-4592 and Rosiglitazone in Healthy Adult Subjects

NCT01376063 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2011-06-20

No results posted yet for this study

Summary

The primary purpose of this study is to assess the effect of multiple doses of FG-4592 on the plasma pharmacokinetic of rosiglitazone in healthy adult subjects.

Conditions

  • Healthy Adult Subjects

Interventions

DRUG

FG-4592

FG-4592 on days 3,5,7,9 Rosiglitazone maleate on days 1 and 9

Sponsors & Collaborators

  • FibroGen

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2010-05-31
Completion
2010-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01376063 on ClinicalTrials.gov